Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone + dexamethasone versus abiraterone + prednisone in metastatic castration-resistant prostate cancer with PSA progression
2017-003189-29Phase 2Active
- Sponsor
- Institut Mutualiste Montsouris
- Start
- Feb 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Abiraterone + dexamethasone with Abiraterone + prednisone (2 arms). Primary endpoint: Progression-free survival. Started Feb 2018; status: active.
02
Drugs
abirateronedexamethasoneprednisone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2017-003189-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003189-29.